{"type":"trials","record":{"id":165,"source_id":"clinicaltrials-gov","external_id":"NCT07567378","title":"CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry","brief_summary":"CARTIZ is a prospective observational clinical registry of adults in Mexico receiving tirzepatide (a dual GLP-1/GIP receptor agonist) under an independent clinical indication - typically type 2 diabetes, insulin resistance, obesity, renal protection, metabolic hypertension, or associated off-label metabolic use. The registry is entirely observational: CARTIZ does not initiate, modify, interrupt, or supply tirzepatide, and does not dictate dose, route, or duration. All pharmacological exposure decisions are made by the treating physician independently of study participation. The registry is operationalized through a four-institute architecture integrating three Mexican National Institutes of Health and one national imaging laboratory. Core 1 (Knee Cartilage Imaging, Ci3M UAM-Iztapalapa) performs bilateral 3T MRI with quantitative T2 mapping at Week 0 and Week 52. Core 2 (Cardiac Imaging,…","overall_status":"Not Yet Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"JULIO GRANADOS MONTIEL","enrollment":30,"countries":["Mexico"],"start_date":"2026-05-01","completion_date":"2029-05-01","last_update_date":"2026-05-12","source_url":"https://clinicaltrials.gov/study/NCT07567378","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-14T02:45:00.719473+00:00","last_seen_at":"2026-09-15T00:18:33.541+00:00","metadata":{"acronym":"CARTIZ","organization":"Universidad La Salle, Mexico","source_has_results":false},"controlled_terms":[],"relevance_confidence":80,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Published automatically with 80% topic confidence after controlled-term evaluation.","quality_checked_at":"2026-09-15T02:15:56.576005+00:00","duplicate_cluster_key":"registry:nct07567378","duplicate_of_id":null,"clinical_trial_topics":[{"topic_slug":"glp-1-therapies","is_published":true,"match_reasons":["Legacy trial evaluated automatically against controlled title, summary, and longevity-context rules."],"matched_fields":["title"],"relevance_score":80,"intelligence_topics":{"name":"GLP-1 therapies","slug":"glp-1-therapies"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/165","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}